Profounda, Inc. announced that it has received the US Food and Drug Administration's Orphan Drug Designation Approval for the use of miltefosine to treat Invasive Candidiasis with Miltefosine. Profounda licensed miltefosine (Impavido
Found this useful? Share it with your team.
